Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698803 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL18294 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL1711599 | 0.83 | USP2 (0.55) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL27036913 | 0.81 | USP2 (0.53) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL31218688 | 0.80 | USP2 (0.51) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| Cyanate SCHEMBL27850415 | 0.79 | CTSK (0.57) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL190131 | 0.79 | USP2 (0.50) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| SCHEMBL27388627 | 0.78 | USP2 (0.62) | USP2SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL16612394 | 0.78 | USP2 (0.62) | USP2SMN1; SMN2CTSKHPGDMEN1 | |
| Cyanate SCHEMBL27835285 | 0.78 | HPGD (0.61) | USP2SMN1; SMN2CTSKHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-11459323-B2 | Monocyclic β-lactam compound for treating bacterial infection | MEDSHINE DISCOVERY INC. (CN) | 2022-10-04 | — | — | US | disclosed |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | VALO HEALTH, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-20210115035-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2021-04-22 | — | — | US | disclosed |
| CN-105712952-B | 2-substituted oxy-5-methylsulfonyl phenyl piperazine amide analogue and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3587411-B1 | 1-(ALPHA-METHYLBENZYL)-5-(PIPERIDINOMETHYL)IMIDAZOLE DERIVATIVES AND USES THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| EP-3747883-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | Medshine Discovery Inc. (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20070112003-A1 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof | CYTOVIA, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1771421-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-11 | — | — | EP | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-7144876-B2 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
| EP-1581213-A1 | 3,5-DISUBSTITUTED- 1,2,4 -OXADIAZOLES AND ANALOGS AS AC TIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004058253-A1 | 3,5-DISUBSTITUTED-[1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | USP2 2755/4885SMN1; SMN2 4460/4885CTSK 811/4885 |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP3, CASP2 | USP2 2465/4885SMN1; SMN2 2855/4885CTSK 1599/4885 |
| US-20070112003-A1 | 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use of thereof | CASP1, CASP3, CASP2 | USP2 2278/4885SMN1; SMN2 3221/4885CTSK 1705/4885 |
| US-11459323-B2 | Monocyclic β-lactam compound for treating bacterial infection | PEPD, COASY, MRPL21 | USP2 2548/4885SMN1; SMN2 2242/4885CTSK 922/4885 |
| US-20210179628-A1 | INHIBITING DEUBIQUITINASE USP25 AND USP28 | USP28, USP25, USP30 | USP2 5/4885SMN1; SMN2 2615/4885CTSK 2243/4885 |
| US-20210115035-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | COASY, BCAT2, PEPD | USP2 2970/4885SMN1; SMN2 2101/4885CTSK 1071/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | USP2 454/4885SMN1; SMN2 1984/4885CTSK 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.